PASI is an index used to express the severity of psoriasis: it combines estimates on the severity of three features (erythema, induration and desquamation) and affected area of skin in each of four regions of the body (head/neck, arms/hands, chest/abdomen/back and buttocks/legs). Summary. The purpose of this study is to establish proof of efficacy of namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at week 12. Enrollment change; Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (clinicaltrials.gov) – Jul 2, 2015 – P2; N120; Recruiting;
Alternative Names: MT-203 Latest Information Update: 08 Mar 2016. Phase II Plaque psoriasis; Rheumatoid arthritis. Feedback / Questions. methyl hydrogen fumarate (XP-23829) – Xenoport, Dr. Reddy’s. Licensing / partnership; Anticipated commercial; Anticipated financing; Dr. Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout.
Efficacy and safety of mavrilimumab, a fully human GM-CSFR alpha monoclonal antibody in patients with rheumatoid arthritis: primary results from the earth explorer 1 study. Efficacy and safety of namilumab (MT203) for plaque psoriasis. Recently, MOR103 has been tested in a safety (Phase Ib) study 9393. Efficacy and safety of namilumab (MT203) for plaque psoriasis. Condition(s): Moderate to Severe Plaque Psoriasis Last Updated: July 15, 2014Completed. Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis.
The goal of clinical trials is to determine if a new test or treatment works and is safe.